Summary:
- The article discusses the Trump administration's purchase of 63 million doses of hydroxychloroquine, a drug that was touted as a potential treatment for COVID-19 early in the pandemic.
- The article argues that the administration's decision to stockpile the drug was a missed opportunity, as it could have been used to treat COVID-19 patients and potentially save lives.
- However, the article also acknowledges that the efficacy of hydroxychloroquine as a COVID-19 treatment was ultimately not proven, and that the decision to stockpile the drug was controversial.